Harmane: an atypical neurotransmitter?

Area of Science:

• Neuroscience
• Neurochemistry
• Pharmacology

Background:

• Harmane is recognized as an endogenous substance interacting with clonidine.
• It is also considered a potential endogenous ligand for imidazoline binding sites.
• Understanding harmane's neurochemical properties is crucial for its role in the central nervous system (CNS).

Purpose of the Study:

• To investigate the neurochemistry of tritiated harmane in the rat brain CNS.
• To examine the uptake and release characteristics of [(3)H]harmane in vitro.
• To determine the transport mechanisms and binding site interactions of harmane.

Main Methods:

• In vitro uptake studies of [(3)H]harmane in rat brain cortex.
• Assessment of uptake in the presence of monoamine uptake blockers (citalopram, nomifensine, nisoxetine).
• Evaluation of imidazoline ligands' effects (rilmenidine, efaroxan, 2-BFI, idazoxan) on [(3)H]harmane uptake.
• Investigation of Na(+) gradient disruption (ouabain, choline chloride) and temperature effects (50°C) on uptake.
• Potassium-evoked release experiments.

Main Results:

• [(3)H]harmane uptake was observed in rat brain cortex at physiological temperatures.
• Monoamine uptake blockers and imidazoline ligands did not significantly affect [(3)H]harmane uptake.
• Uptake was Na(+)-independent and not inhibited by ouabain or choline chloride.
• High temperatures (50°C) did not impede uptake, suggesting a non-physiological transporter.
• Potassium failed to evoke the release of preloaded [(3)H]harmane.

Conclusions:

• Harmane's transport in the rat brain cortex is distinct from monoamine uptake systems.
• Imidazoline binding sites do not appear to be involved in harmane uptake.
• The transport mechanism is Na(+)-independent and may involve a non-physiological transporter.
• Harmane's release properties do not resemble those of conventional neurotransmitters, despite being a candidate endogenous ligand for imidazoline binding sites.